4
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Suppressive Effect of Monocytes in Vitro in Patients with Carcinoma of the Uterine Cervix

, &
Pages 619-624 | Received 28 Mar 1985, Accepted 09 May 1985, Published online: 03 Aug 2009
 

Abstract

The adherent cell fraction (AdC) of human peripheral blood mononuclear cells (PBM) contains two cell types of opposing function in vitro. Dendritic cells (DC) act as antigen-presenting cells (APC) in vitro, while monocytes (Mo) have a suppressive effect on antigen activation of T cells. in this report we show that patients with cervical carcinoma have a significantly increased number of suppressive Mo compared with healthy controls. the T cell response to Herpes Simplex Virus (HSV-1) and PPD was about the same in the two groups, but after removal of Mo by adherence a significantly higher T cell response was seen among the patients with advanced stage (Figo stage IIb–IVa) compared with patients in early stage (Figo stage Ia–IIa) and healthy controls. These observations indicate that patients with cervical carcinoma have 1) an increased number of T cells reactive with HSV, and 2) normal DC function. the relative suppression expressed on a per Mo basis was the same in all groups, which indicates that the increased suppression in the patients was caused by an increased number of Mo, and not by changes in their activation state.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.